Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-1.09 |
-0.83 |
0.26 |
23.85% |
2024-03-12 |
2023-12 |
-2.36 |
-1.81 |
0.55 |
23.31% |
2023-11-07 |
2023-09 |
-2.06 |
-2.27 |
-0.21 |
-10.19% |
2023-08-08 |
2023-06 |
-3.1 |
-2.05 |
1.05 |
33.87% |
2023-05-09 |
2023-03 |
-4.09 |
-4.24 |
-0.15 |
-3.67% |
2023-03-07 |
2022-12 |
-2.1 |
-2.61 |
-0.51 |
-24.29% |
Date |
Firm |
Action |
From |
To |
2023-08-08 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-05-09 |
Oppenheimer |
Upgrade |
Perform |
Outperform |
2023-03-07 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-02-11 |
COHEN YUVAL |
Chief Executive Officer |
84.40K |
Stock Award(Grant) |
2024-03-07 |
CORMORANT ASSET MANAGEMENT ,L.P |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2020-03-16 |
DISCORDIA ROBERT PAUL |
Chief Operating Officer |
35.49K |
Purchase |
2019-03-14 |
HOCHMAN DAVID P |
Director |
0.00 |
Purchase |
2024-01-25 |
HOLMER ALAN F |
Director |
1.38K |
Conversion of Exercise of derivative security |
2019-03-14 |
JENKINS JOHN KENNETH M.D. |
Director |
1000 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Ikarian Capital, LLC |
192.26K |
1.51M |
4.35% |
2023-06-29 |
Vanguard Group Inc |
179.46K |
1.41M |
4.06% |
2023-06-29 |
Sio Capital Management, LLC |
150.00K |
1.18M |
3.39% |
2023-06-29 |
Blackrock Inc. |
81.96K |
642.60K |
1.85% |
2023-06-29 |
Boothbay Fund Management, LLC |
37.98K |
297.73K |
0.86% |
2023-06-29 |
Geode Capital Management, LLC |
32.87K |
257.66K |
0.74% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
112.02K |
878.25K |
2.53% |
2023-06-29 |
Vanguard Extended Market Index Fund |
62.06K |
486.54K |
1.40% |
2023-07-30 |
DFA U.S. Small Cap Series |
23.12K |
166.46K |
0.52% |
2023-05-30 |
Fidelity Extended Market Index Fund |
18.51K |
175.31K |
0.42% |
2023-08-30 |
iShares Micro Cap ETF |
8.74K |
63.79K |
0.20% |
2023-05-30 |
Fidelity Total Market Index Fund |
5.25K |
49.67K |
0.12% |
Split |
Date |
1 : 30 |
2023-02-14 |